Immune system changes may drive aggressiveness of recurrent tumors

Nearly half of the 700,000 cancer patients who undergo surgical removal of a primary tumor each year suffer a recurrence of their disease at some point, and many of those patients will eventually die from their disease. The traditional view of recurrent tumors is that they are resistant to therapy because they've acquired additional genetic mutations that make them more aggressive and impervious to drugs. Now, however, researchers at the Perelman School of Medicine at the University of Pennsylvania show in an animal model that the enhanced aggressiveness of recurrent tumors may be due to changes in the body's immune response. The findings are published this week in the Proceedings of the National Academy of Sciences.

"Typically when a patient has a , their oncologist treats them, much like they treated them for the primary tumor – with drugs aimed at the themselves. But we've found that it might be better to attack the tumor cells and knock down the bad immune cells that are protecting the tumor," says senior study author Sunil Singhal, MD, assistant professor of Surgery and director, Thoracic Surgery Research Laboratory at the Perelman School of Medicine.

To assess the impact of anti-cancer vaccines on primary and recurrent tumors, the researchers immunized mice that had a primary or a recurrent tumor in their flank. Although both groups of animals developed an immune response to the vaccine, only the primary-tumor animals showed in response to the vaccine. The recurrent tumors appeared unaffected by the vaccine response. Moreover, this pattern held for several different vaccines.

Despite the prevailing models of tumor recurrence—which emphasize in the tumor cells themselves—Singhal and colleagues could not find substantial genetic or behavior differences in the recurrent versus primary tumors that might account for the pattern of response.

By contrast, when the team looked at the types of immune cells in and around the tumor, Singhal's team saw a big difference. The recurrent-tumor mice had a large increase in the number of regulatory T cells, compared with primary-tumor animals. That could be important, says Singhal, because T regulatory cells are responsible for holding other in check and blocking immune responses.

Additionally, macrophages that protect the tumor cells from immune system also increased in number and activity in the recurrent-tumor animals.

Remarkably, when the researchers treated recurrent-tumor animals with drugs that block macrophage activity, tumor growth slowed significantly. However, the same drugs had no effect on primary-tumor animals.

Singhal says it is not clear exactly what triggers the immune system changes, but whatever it is appears to happen at the time of surgery. His group has already started looking for alterations in signaling molecules.

In the meantime, though, he notes that there are newly approved drugs and experimental agents that block regulatory T cells. Given his team's new results, he thinks testing these agents in patients with recurrent disease – in combination with drugs that attack the tumor cells themselves – could be an important advance for patients.

"We could impact the outcomes of as many as 250,000 patients a year, if this strategy works," he said.

Related Stories

Tumor environment keeps tumor-fighting T cells away

Sep 19, 2011

Tumors have an arsenal of tricks to help them sidestep the immune system. A study published on September 19 in the Journal of Experimental Medicine reveals a new trick -- the ability to keep tumor-fighting T cells out by ...

Drug/radiation combo may help shrink established tumors

Aug 25, 2008

Researchers may be closer to understanding why anti-cancer drugs such as Ipilimumab, which boost the tumor-killing power of immune cells, haven't fared well in clinical trials. The new study, which describes a way to enhance ...

Researchers develop novel anti-tumor vaccine

Oct 02, 2008

A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact ...

Recommended for you

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

Dec 19, 2014

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

cantdrive85
1 / 5 (1) Dec 27, 2012
Nearly half of the 700,000 cancer patients who undergo surgical removal of a primary tumor each year suffer a recurrence of their disease at some point, and many of those patients will eventually die from their disease.


This is why western medicine fails so miserably in treating these types of ailments. Merely removing the tumor in no way addresses why the tumor grew in the first place, they are treating the symptoms and not root cause. There is very little hope of finding a "cure" to cancer, it is a far too profitable business.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.